Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
Trump Administration Plans Chip Tariff Exemptions for Big Tech Amid AI Data Center Push 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units 
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
EMERYVILLE, Calif., Nov. 14, 2017 -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that Stephen J. Farr, Ph.D., President and CEO of Zogenix, will present a corporate overview at the Stifel 2017 Healthcare Conference, taking place November 14-15, 2017, in New York, NY.
Zogenix Presentation Details
Date: Wednesday, November 15, 2017
Time: 8:45 am Eastern Time / 5:45 am Pacific Time
Location: New York, NY – Lotte New York Palace Hotel
The presentation will be webcast live and archived for 30 days on Zogenix's Investor Relations website at ir.zogenix.com.
About Zogenix
Zogenix, Inc. (Nasdaq:ZGNX) is a pharmaceutical company committed to developing and commercializing CNS therapies that address specific clinical needs for people living with orphan and other CNS disorders who need innovative treatment alternatives to improve their daily functioning.
For more information, visit www.zogenix.com.
CONTACT: Investors: Andrew McDonald
Founding Partner, LifeSci Advisors LLC
646-597-6987 | [email protected]
